Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma

BackgroundGemcitabine is a promising drug for cholangiocarcinoma treatment. However, the kinetics and metabolism of this drug in cholangiocarcinoma treatment are not well defined. We aimed to investigate the potential clinical role of gemcitabine metabolism-related genes in the gemcitabine sensitivity of cholangiocarcinoma and identify and characterize novel gemcitabine resistance-related genes.MethodsExpressions of genes related to gemcitabine sensitivity and gemcitabine metabolism were measured in 10 cholangiocarcinoma cell lines, and the association between gene expression and gemcitabine sensitivity was evaluated. Furthermore, gemcitabine-resistant cell lines were established from YSCCC cells and subjected to genome-wide microarray analysis. The 2-fold upregulated and downregulated genes were then subjected to pathway analysis.Resultsp53R2 mRNA expression was significantly higher in gemcitabine-resistant cell lines (IC50 > 1000 nM), and all subunits of ribonucleotide reductase were upregulated in the established gemcitabine-resistant cell lines. Microarray analysis revealed that the upregulated genes in the resistant cells belonged to the glutathione and pyrimidine metabolism pathways, and that the downregulated genes belonged to the N-glycan biosynthesis pathway.ConclusionsIncreased expression of p53R2 may predict gemcitabine resistance, and upregulated RNR activity may influence gemcitabine resistance in cholangiocarcinoma cells. Glutathione pathway-related genes were induced by continuous exposure to gemcitabine and may contribute to gemcitabine resistance.

[1]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[2]  C. Iacobuzio-Donahue,et al.  Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and Survival , 2006, Clinical Cancer Research.

[3]  H. Groen,et al.  Genetic factors influencing Pyrimidine-antagonist chemotherapy , 2005, The Pharmacogenomics Journal.

[4]  A. Mazo,et al.  Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[6]  Erik Schrumpf,et al.  Diagnosis and treatment of cholangiocarcinoma , 2004, Current gastroenterology reports.

[7]  Y. Yen,et al.  Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells. , 2002, Anticancer research.

[8]  M. Thomas.  Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. , 2007, Critical reviews in oncology/hematology.

[9]  S. Ashley,et al.  RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine , 2004, Oncogene.

[10]  John R. Mackey,et al.  Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma , 2009, Clinical Cancer Research.

[11]  M. Olnes,et al.  A Review and Update on Cholangiocarcinoma , 2004, Oncology.

[12]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[13]  H. Ueno,et al.  Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  V. Heinemann,et al.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.

[15]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[16]  Ryuzo Ueda,et al.  Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non‐small cell lung cancer , 2004, Cancer science.

[17]  Benjamin Rs.  Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. , 1995 .

[18]  Y. Yen,et al.  Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. , 1999, Cancer research.

[19]  Zhe-Sheng Chen,et al.  Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. , 2009, Cancer research.

[20]  Y. Takeda,et al.  Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer , 2007, International journal of cancer.

[21]  F. Eckel,et al.  Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials , 2007, British Journal of Cancer.

[22]  L. Gelbert,et al.  An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines , 2004, Cancer Research.

[23]  D. Townsend,et al.  The role of glutathione-S-transferase in anti-cancer drug resistance , 2003, Oncogene.

[24]  V. Heinemann,et al.  Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. , 1995, Seminars in oncology.

[25]  J. Mackey,et al.  Nucleoside analogues and nucleobases in cancer treatment. , 2002, The Lancet. Oncology.